India's exports of active pharma ingredients at Rs 41,500 cr surpassed imports in FY25
Analysis of this story by et_companies · 10 Mar 2026, 5:14 PM IST (about 2 months ago)
AI Analysis
The Indian pharma sector is focusing on reducing import dependence for APIs, a critical component. Government support through PLI schemes is boosting domestic manufacturing.
Trading Insight
Positive for domestic API manufacturers; identify companies with strong API production capabilities and PLI scheme beneficiaries.
Quick check: SUNPHARMA bullish bias (overbought), CIPLA neutral (+0.8% 1d).
Key Evidence
- •API exports reached Rs 41,500 crore in FY25.
- •API imports were Rs 39,215 crore in FY25.
- •The government's Production Linked Incentive (PLI) scheme aims for self-reliance and reduced import connections, especially with China.
- •Risk flag: Global supply chain disruptions could still impact raw material availability.
- •Risk flag: Intense competition among domestic players.
Sectors:pharma
Sources and updates
Original source: et_companies
Published: 10 Mar 2026, 5:14 PM IST
Last updated on Anadi News: 10 Mar 2026, 5:42 PM IST
AI-powered analysis by
Anadi Algo News